120 related articles for article (PubMed ID: 14729634)
21. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.
Condra JH; Holder DJ; Schleif WA; Blahy OM; Danovich RM; Gabryelski LJ; Graham DJ; Laird D; Quintero JC; Rhodes A; Robbins HL; Roth E; Shivaprakash M; Yang T; Chodakewitz JA; Deutsch PJ; Leavitt RY; Massari FE; Mellors JW; Squires KE; Steigbigel RT; Teppler H; Emini EA
J Virol; 1996 Dec; 70(12):8270-6. PubMed ID: 8970946
[TBL] [Abstract][Full Text] [Related]
22. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Zhang J; Frolov I; Russell SJ
J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
[TBL] [Abstract][Full Text] [Related]
23. A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease.
Martínez MA; Cabana M; Parera M; Gutierrez A; Esté JA; Clotet B
Antimicrob Agents Chemother; 2000 May; 44(5):1132-9. PubMed ID: 10770741
[TBL] [Abstract][Full Text] [Related]
24. Update on HIV protease inhibitors.
Vella S
AIDS Clin Care; 1995 Oct; 7(10):79-82, 88. PubMed ID: 11362832
[TBL] [Abstract][Full Text] [Related]
25. Multitracer positron emission tomographic imaging of exogenous gene expression mediated by a universal herpes simplex virus 1 amplicon vector.
Kummer C; Winkeler A; Dittmar C; Bauer B; Rueger MA; Rueckriem B; Heneka MT; Vollmar S; Wienhard K; Fraefel C; Heiss WD; Jacobs AH
Mol Imaging; 2007; 6(3):181-92. PubMed ID: 17532884
[TBL] [Abstract][Full Text] [Related]
26. Herpes simplex virus type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration.
Wang Y; Camp SM; Niwano M; Shen X; Bakowska JC; Breakefield XO; Allen PD
J Virol; 2002 Jul; 76(14):7150-62. PubMed ID: 12072515
[TBL] [Abstract][Full Text] [Related]
27. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
28. Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.
Shah AC; Price KH; Parker JN; Samuel SL; Meleth S; Cassady KA; Gillespie GY; Whitley RJ; Markert JM
J Virol; 2006 Aug; 80(15):7308-15. PubMed ID: 16840311
[TBL] [Abstract][Full Text] [Related]
29. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
[TBL] [Abstract][Full Text] [Related]
30. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
Otsuki A; Patel A; Kasai K; Suzuki M; Kurozumi K; Chiocca EA; Saeki Y
Mol Ther; 2008 Sep; 16(9):1546-55. PubMed ID: 18648350
[TBL] [Abstract][Full Text] [Related]
31. HSV-1 amplicon-mediated post-transcriptional inhibition of Rad51 sensitizes human glioma cells to ionizing radiation.
Saydam O; Saydam N; Glauser DL; Pruschy M; Dinh-Van V; Hilbe M; Jacobs AH; Ackermann M; Fraefel C
Gene Ther; 2007 Aug; 14(15):1143-51. PubMed ID: 17495946
[TBL] [Abstract][Full Text] [Related]
32. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
33. Human immunodeficiency virus type 1 Vif-derived peptides inhibit the viral protease and arrest virus production.
Baraz L; Friedler A; Blumenzweig I; Nussinuv O; Chen N; Steinitz M; Gilon C; Kotler M
FEBS Lett; 1998 Dec; 441(3):419-26. PubMed ID: 9891983
[TBL] [Abstract][Full Text] [Related]
34. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
35. Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation.
Iga M; Matsuda Z; Okayama A; Sugiura W; Hashida S; Morishita K; Nagai Y; Tsubouchi H
J Virol Methods; 2002 Oct; 106(1):25-37. PubMed ID: 12367727
[TBL] [Abstract][Full Text] [Related]
36. Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model.
Kuriyama N; Kuriyama H; Julin CM; Lamborn KR; Israel MA
Cancer Res; 2001 Mar; 61(5):1805-9. PubMed ID: 11280727
[TBL] [Abstract][Full Text] [Related]
37. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
[TBL] [Abstract][Full Text] [Related]
38. A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure.
Stürmer M; Staszewski S; Doerr HW; Hertogs K
AIDS Res Hum Retroviruses; 2003 Nov; 19(11):967-8. PubMed ID: 14678603
[TBL] [Abstract][Full Text] [Related]
39. Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo.
Lee T; Laco GS; Torbett BE; Fox HS; Lerner DL; Elder JH; Wong CH
Proc Natl Acad Sci U S A; 1998 Feb; 95(3):939-44. PubMed ID: 9448264
[TBL] [Abstract][Full Text] [Related]
40. Quantitative assessment of in vivo HIV protease activity using genetically engineered QD-based FRET probes.
Cella LN; Biswas P; Yates MV; Mulchandani A; Chen W
Biotechnol Bioeng; 2014 Jun; 111(6):1082-7. PubMed ID: 24473897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
